BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 19948364)

  • 1. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment.
    Molinuevo JL; Berthier ML; Rami L
    Arch Gerontol Geriatr; 2011; 52(1):18-22. PubMed ID: 19948364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
    Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
    Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
    Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J
    J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between quality of life, Mini-Mental State Examination, and the Instrumental Activities of Daily Living in patients with Alzheimer's disease.
    Wlodarczyk JH; Brodaty H; Hawthorne G
    Arch Gerontol Geriatr; 2004; 39(1):25-33. PubMed ID: 15158578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of responders and non-responders to long-term donepezil treatment.
    Inoue J; Hoshino R; Nojima H; Ishida W; Okamoto N
    Psychogeriatrics; 2010 Jun; 10(2):53-61. PubMed ID: 20738808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive predictors of donepezil therapy response in Alzheimer disease.
    Saumier D; Murtha S; Bergman H; Phillips N; Whitehead V; Chertkow H
    Dement Geriatr Cogn Disord; 2007; 24(1):28-35. PubMed ID: 17495473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    Passmore AP; Bayer AJ; Steinhagen-Thiessen E
    J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
    Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
    Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
    Choi SH; Kim SY; Na HR; Kim BK; Yang DW; Kwon JC; Park MY
    Dement Geriatr Cogn Disord; 2008; 25(5):445-50. PubMed ID: 18401173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA; Paramadevan J; Abdullah L; Mullan M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.